The pharma giant said amycretin helped patients lose weight and reduce blood-sugar levels in pill and injection forms during a mid-stage trial, lifting shares in the company.

Novo Nordisk, whose shares have stumbled this year, on Tuesday announced a positive trial result for a weight-loss drug in development.

Eli Lilly announced trial results for its weight-loss medication, orforglipron, in August. Orforglipron is a once-daily oral GLP-1 pill being studied for the treatment of type 2 diabetes and obesity, as it is designed to help lower blood sugar and support weight loss.

The Food and Drug Administration is set to treat application under its priority program that seeks to accelerate the review of products that address major health priorities.

Novo Nordisk is now offering people who pay out of pocket a steep discount for select doses of Ozempic and Wegovy.

Novo Nordisk’s stock tumbles after its oral GLP-1 drug didn’t show a statistically significant benefit over a placebo against Alzheimer’s.